参考文献/References:
[1] 王增武,刘静,李建军,等. 中国血脂管理指南（2023年）[J]. 中国循环杂志,2023,38(3):237-271.
[2] 中国心血管健康与疾病报告编写组,胡盛寿. 中国心血管健康与疾病报告2022概要[J]. 中国循环杂志,2023,38(6):583-612.
[3] Ference BA,Ginsberg HN,Graham I,et al. Low-density lipoproteins cause atherosclerotic
cardiovascular disease. 1. Evidence from genetic,epidemiologic,and clinical studies. A
consensus statement from the European Atherosclerosis Society Consensus Panel[J]. Eur
Heart J,2017,38(32):2459-2472.
[4] Baigent C,Blackwell L,Emberson J,et al. Efficacy and safety of more intensive lowering ofLDL cholesterol:a meta-analysis of data from 170,000 participants in 26 randomised trials[J]. Lancet,2010,376(9753):1670-1681.
[5] Bonovas S,Nikolopoulos G,Sitaras NM. Efficacy and safety of more intensive lowering ofLDL cholesterol[J]. Lancet,2011,377(9767):715-716.
[6] 李永林,司春婴,顾问,等. PCSK9抑制剂和Inclisiran在动脉粥样硬化中的研究进展[J]. 医学研究生学报,2021,34(4):439-443.
[7] 谢坤,李勇. 高甘油三酯血症临床管理多学科专家共识[J]. 中国循环杂志,2023,38(6):621-633.
[8] Cannon CP,Blazing MA,Giugliano RP,et al. Ezetimibe added to statin therapy after acute
coronary syndromes[J]. N Engl J Med,2015,372(25):2387-2397.
[9] 侯立强,孙燕,任雷,等. 新型siRNA药物：inclisiran在降脂治疗中的研究进展[J]. 中国医药导刊,2023,25(2):140-145.
[10] Gallego-Colon E,Daum A,Yosefy C. Statins and PCSK9 inhibitors:a new lipid-lowering
therapy[J]. Eur J Pharmacol,2020,878:173114.
[11] Shadid M,Badawi M,Abulrob A. Antisense oligonucleotides:absorption,distribution,metabolism,and excretion[J]. Expert Opin Drug Metab Toxicol,2021,17(11):1281-1292.
[12] Shen X,Corey DR. Chemistry,mechanism and clinical status of antisense oligonucleotides
and duplex RNAs[J]. Nucleic Acids Res,2018,46(4):1584-1600.
[13] Khvorova A. Oligonucleotide therapeutics—A new class of cholesterol-lowering drugs[J].
N Engl J Med,2017,376(1):4-7.
[14] Brown CR,Gupta S,Qin J,et al. Investigating the pharmacodynamic durability of
GalNAc-siRNA conjugates[J]. Nucleic Acids Res,2020,48(21):11827-11844.
[15] Bogaert B,Sauvage F,Guagliardo R,et al. A lipid nanoparticle platform for mRNA delivery through repurposing of cationic amphiphilic drugs[J]. J Control Release,2022,350:256-270.
[16] Crooke ST,Witztum JL,Bennett CF,et al. RNA-targeted therapeutics[J]. Cell Metab,2018,27(4):714-739.
[17] Lu Y,Huang W,Li M,et al. Exosome-based carrier for RNA delivery:progress and
challenges[J]. Pharmaceutics,2023,15(2):598
[18] Henney NC,Banach M,Penson PE. RNA silencing in the management of dyslipidemias[J].
Curr Atheroscler Rep,2021,23(11):69.
[19] Weng Y,Xiao H,Zhang J,et al. RNAi therapeutic and its innovative biotechnological
evolution[J]. Biotechnol Adv,2019,37(5):801-825.
[20] 赵紫楠,史琛,胡欣,等. 小干扰RNA降脂药物药学专家共识[J]. 中国医院药学杂志,2024,44(1):9-17.
[21] 张磊,智昱,刘丽,等. 新型小干扰RNA降脂药物Inclisiran研究进展[J]. 中国心血管杂志,2022,27(2):176-178.
[22] Ray KK,Wright RS,Kallend D,et al. Two phase 3 trials of inclisiran in patients with
elevated LDL cholesterol[J]. N Engl J Med,2020,382(16):1507-1519.
[23] Wright RS,Ray KK,Raal FJ,et al. Pooled patient-level analysis of inclisiran trials in
patients with familial hypercholesterolemia or atherosclerosis[J]. J Am Coll Cardiol,2021,77(9):1182-1193.
[24] Ray KK,Raal FJ,Kallend DG,et al. Inclisiran and cardiovascular events:a patient-level
analysis of phase Ⅲ trials[J]. Eur Heart J,2023,44(2):129-138.
[25] Cordero A,Santos-Gallego CG,Facila L,et al. Estimation of the major cardiovascular event
prevention with Inclisiran[J]. Atherosclerosis,2020,313:76-80.
[26] Kosmas CE,Munoz EA,Skavdis A,et al. Inclisiran for the treatment of cardiovascular
disease:a short review on the emerging data and therapeutic potential[J]. Ther Clin Risk
Manag,2020,16:1031-1037.
[27] Khan SA,Naz A,Qamar MM,et al. Meta-analysis of inclisiran for the treatment of
hypercholesterolemia[J]. Am J Cardiol,2020,134:69-73.
[28] Ray KK,Stoekenbroek RM,Kallend D,et al. Effect of 1 or 2 doses of inclisiran on
low-density lipoprotein cholesterol levels:one-year follow-up of the ORION-1 r andomized
clinical t rial[J]. JAMA Cardiol,2019,4(11):1067-1075.
[29] Raal FJ,Kallend D,Ray KK,et al. Inclisiran for the treatment of heterozygous familial
hypercholesterolemia[J]. N Engl J Med,2020,382(16):1520-1530.
[30] Raal F,Durst R,Bi R,et al. Efficacy,safety,and tolerability of inclisiran in patients with
homozygous familial hypercholesterolemia:results from the ORION-5 randomized clinical
trial[J]. Circulation,2024,149(5):354-362
[31] Norata GD,Tibolla G,Catapano AL. Targeting PCSK9 for hypercholesterolemia[J]. Annu
Rev Pharmacol Toxicol,2014,54:273-293.
[32] Lagace TA,Curtis DE,Garuti R,et al. Secreted PCSK9 decreases the number of LDL
receptors in hepatocytes and in livers of parabiotic mice[J]. J Clin Invest,2006,116(11):2995-3005.
[33] Huynh K. Dyslipidaemia. Assessing the efficacy and safety of evolocumab and alirocumab[J]. Nat Rev Cardiol,2015,12(5):261.
[34] Mulder J,Galema-Boers A,Roeters VLJ. First clinical experiences with inclisiran in a
real-world setting[J]. J Clin Lipidol,2023,17(6):818-827.
[35] Cunningham D,Danley DE,Geoghegan KF,et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia[J]. Nat Struct Mol Biol,2007,14(5):413-419.
[36] Kallend D,Stoekenbroek R,He Y,et al. Pharmacokinetics and pharmacodynamics of
inclisiran,a small interfering RNA therapy,in patients with hepatic impairment[J]. J Clin
Lipidol,2022,16(2):208-219.
[37] Wright RS,Collins MG,Stoekenbroek RM,et al. Effects of renal impairment on the
pharmacokinetics,efficacy,and safety of inclisiran:an analysis of the ORION-7 and
ORION-1 studies[J]. Mayo Clin Proc,2020,95(1):77-89.
[38] Boren J,Chapman MJ,Krauss RM,et al. Low-density lipoproteins cause atherosclerotic
cardiovascular disease:pathophysiological,genetic,and therapeutic insights:a consensus
statement from the European Atherosclerosis Society Consensus Panel[J]. Eur Heart J,2020,41(24):2313-2330.
[39] O’Donoghue ML,Rosenson RS,Gencer B,et al. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease[J]. N Engl J Med,2022,387(20):1855-1864.
[40] O’Donoghue ML,Rosenson RS,Gencer B,等. Olpasiran治疗动脉粥样硬化性心血管疾病患者的临床研究[J]. 中国临床药理学杂志,2023,39(4):482.
[41] Ginsberg HN,Goldberg IJ. Broadening the scope of dyslipidemia therapy by targeting
APOC3 (apolipoprotein C3) and ANGPTL3(angiopoietin-like protein 3)[J]. Arterioscler
Thromb Vasc Biol,2023,43(3):388-398.
[42] Mercep I,Strikic D,Sliskovic AM,et al. New therapeutic approaches in treatment of
dyslipidaemia—A narrative review[J]. Pharmaceuticals(Basel) ,2022,15(7):839.
[43] Lamb YN. Correction to:inclisiran:first approval[J]. Drugs,2021,81(9):1129.
相似文献/References:
[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(6):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]李乐亮,综述,李萍,等.炎症标志物与颈动脉粥样斑块的稳定性[J].心血管病学进展,2016,(3):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
LI Leliang,LI Ping.Stability of Inflammatory Markers and Carotid Artery Plaque[J].Advances in Cardiovascular Diseases,2016,(6):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
[3]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[4]耿春晖 关秀茹.MicroRNA作为动脉粥样硬化的诊断生物标志物的研究进展[J].心血管病学进展,2019,(7):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
GENG Chunhui,GUAN Xiuru.microRNA as a Diagnostic Biomarker for Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(6):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
[5]乐健 何胜虎.前蛋白转化酶枯草溶菌素9致动脉粥样硬化的机制研究进展[J].心血管病学进展,2019,(7):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
YUE Jian,HE Shenghu.Advances in the mechanism of PCSK9-induced atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(6):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
[6]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(6):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[7]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(6):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[8]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(6):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[9]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(6):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[10]武亚琳,梁斌,杨志明.NLRP3/IL-1β途径的促动脉粥样硬化作用及临床应用[J].心血管病学进展,2019,(6):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
WU Yalin,LIANG Bin,YANG Zhiming.The Role of NLRP3/IL-1in Atherosclerosis and Clinical Application[J].Advances in Cardiovascular Diseases,2019,(6):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
[11]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(6):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[12]邹先明 赵然尊.长链非编码RNA ANRIL与心血管疾病的研究进展[J].心血管病学进展,2020,(2):167.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.017]
ZOU Xianming,ZHAO Ranzun.Long Non-Coding RNA ANRIL and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(6):167.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.017]
[13]毕一鸣 曹丰.内皮细胞功能异常与动脉粥样硬化的研究进展[J].心血管病学进展,2022,(2):150.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.014]
BI YimingCAO Feng.Vascular Endothelial Cells Involved?n the Pathophysiological Process of Atherosclerosis[J].Advances in Cardiovascular Diseases,2022,(6):150.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.014]
[14]董博华 吴雨晴 扈家源 魏宇涵 张桂彬 赵亚楠 陈喆 杨文琦.细颗粒物暴露对急性冠脉综合征作用机制的研究进展[J].心血管病学进展,2023,(2):132.[doi:10.16806/j.cnki.issn.1004-3934.2023.02.008]
DONG Bohua,WU Yuqing,HU Jiayuan,et al.Research Progress on the Mechanism of PM2.5 Exposure on Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2023,(6):132.[doi:10.16806/j.cnki.issn.1004-3934.2023.02.008]
[15]刘张弛 杨波.瞬时受体电位香草酸亚型4在心血管疾病中的研究进展[J].心血管病学进展,2023,(9):777.[doi:10.16806/j.cnki.issn.1004-3934.2023.09.000]
LIU Zhangchi,YANG Bo?/html>.Transient Receptor Potential Vanilloid 4 in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2023,(6):777.[doi:10.16806/j.cnki.issn.1004-3934.2023.09.000]
[16]龙雪蛟 洪绍彩 贝俊杰.血小板参数在心血管疾病中的研究进展[J].心血管病学进展,2023,(10):945.[doi:10.16806/j.cnki.issn.1004-3934.2023.10.018]
LONG Xuejiao,HONG Shaocai,BEI Junjie.Progress of Platelet Parameters in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2023,(6):945.[doi:10.16806/j.cnki.issn.1004-3934.2023.10.018]
[17]黄佳宇 熊安琪 蒋弼瀛 陈文佳.液-液相分离在心血管疾病中的研究进展[J].心血管病学进展,2024,(7):603.[doi:10.16806/j.cnki.issn.1004-3934.2024.07.007]
HUANG Jiayu,XIONG Anqi,JIANG Biying,et al.Liquid-Liquid Phase Separation in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2024,(6):603.[doi:10.16806/j.cnki.issn.1004-3934.2024.07.007]
[18]杜孝亮 徐静 李樊丹 杨浩 吕湛.残余胆固醇在动脉粥样硬化性心血管疾病中的作用机制研究进展[J].心血管病学进展,2024,(8):732.[doi:10.16806/j.cnki.issn.1004-3934.202.08.013]
DU Xiaoliang,XU Jing,LI Fandan,et al.Action Mechanism of Remnant Cholesterol and Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2024,(6):732.[doi:10.16806/j.cnki.issn.1004-3934.202.08.013]
[19]丁芳芳 廖付军 鲍海龙 李洁琪.非高密度脂蛋白胆固醇与动脉粥样硬化性心血管疾病关系的研究进展[J].心血管病学进展,2024,(9):806.[doi:10.16806/j.cnki.issn.1004-3934.2024.09.009]
DING Fangfang,LIAO Fujun,BAO Hailong,et al.The Relationship Between Non-High-Density Lipoprotein Cholesterol and Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2024,(6):806.[doi:10.16806/j.cnki.issn.1004-3934.2024.09.009]